Literature DB >> 15289859

Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.

Yuta Katayama1, Akira Sakai, Yoshiko Okikawa, Naohide Oue, Hideki Asaoku, Ayako Sasaki, Fumio Imanaka, Takako Tsujimoto, Yasuo Takimoto, Rie Masuda, Nanae Nakaju, Takemi Otsuki, Wataru Yasui, Akiro Kimura.   

Abstract

Cyclin D1 is a positive-regulator of the cell cycle and is overexpressed in myeloma cells with t(11;14)(q13;q32). First, we analyzed whether there was a correlation between cyclin D1 overexpression and the presence of Ki67-positive myeloma cells in multiple myeloma (MM). Cyclin D1 overexpression was examined by competitive RT-PCR. Then we found these two markers were present independently in a given case. FISH analysis revealed that cyclin D1 over-expression was caused by t(11;14)(q13;q32) or extra copies of B-cell leukemia/lymphoma-1 (BCL-1/CCND1), and unknown mechanism without them. We compared the gene expression between myeloma cells with cyclin D1 overexpression and those without it using cDNA microarray analysis. Analysis of the expression profiles showed that the significantly up-regulated genes included cyclin D1, cell division cycle 37 (CDC37) and B-cell leukemia/lymphoma-2 (BCL-2), while the down-regulated genes included cyclin D2 and CD9 antigen (p24) in MM cases with cyclin D1 overexpression. However, hierarchical clustering analysis of the data showed that myeloma cells of MM cases with cyclin D1 overexpression could not be distinguished clearly from those without it. Real-time RT-PCR showed that the expression of CDC37 gene was significantly up-regulated in MM patients with cyclin D1 overexpression compared with those without it (p=0.0418). However, there was no significant difference in BCL-2 gene (p=0.5748). These results suggested that MM cases with cyclin D1 overexpression do not constitute a specific group, and cyclin D1 overexpression may not be caused only by abnormality of the BCL-1/CCND1 gene. The CDC37 may collaborate with cyclin D1 in progression of MM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289859

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

Review 1.  Targeting the oncogene and kinome chaperone CDC37.

Authors:  Phillip J Gray; Thomas Prince; Jinrong Cheng; Mary Ann Stevenson; Stuart K Calderwood
Journal:  Nat Rev Cancer       Date:  2008-05-30       Impact factor: 60.716

2.  Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s.

Authors:  Meirong Zang; Jiaojiao Guo; Lanting Liu; Fengyan Jin; Xiangling Feng; Gang An; Xiaoqi Qin; Yangbowen Wu; Qian Lei; Bin Meng; Yinghong Zhu; Yongjun Guan; Shuhui Deng; Mu Hao; Yan Xu; Dehui Zou; Minghua Wu; Lugui Qiu; Wen Zhou
Journal:  Oncogenesis       Date:  2020-03-05       Impact factor: 7.485

3.  Cell surface Cdc37 participates in extracellular HSP90 mediated cancer cell invasion.

Authors:  Avraam El Hamidieh; Nicholas Grammatikakis; Evangelia Patsavoudi
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

4.  Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins.

Authors:  J R Smith; E de Billy; S Hobbs; M Powers; C Prodromou; L Pearl; P A Clarke; P Workman
Journal:  Oncogene       Date:  2013-12-02       Impact factor: 9.867

Review 5.  Molecular cochaperones: tumor growth and cancer treatment.

Authors:  Stuart K Calderwood
Journal:  Scientifica (Cairo)       Date:  2013-04-17

6.  Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts.

Authors:  Wei Wei; Song Wu; Xiaolin Wang; Chris Kin-Wai Sun; Xiaoyang Yang; Xinrui Yan; Mei-Sze Chua; Samuel So
Journal:  Oncotarget       Date:  2014-07-30

Review 7.  ERK5 and Cell Proliferation: Nuclear Localization Is What Matters.

Authors:  Nestor Gomez; Tatiana Erazo; Jose M Lizcano
Journal:  Front Cell Dev Biol       Date:  2016-09-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.